Introduction {#Sec1}
============

Atherosclerosis, a chronic inflammatory disease that leads to plaque deposition in arteries and is associated with increased levels of low-density lipoprotein cholesterol (LDL-C) \[[@CR1]\], is the leading cause of cardiovascular diseases (CVDs) \[[@CR2]\]. Atherosclerotic cardiovascular disease (ASCVD) is a common cause of myocardial infarction (MI) and stroke and can lead to a need for revascularization procedures such as percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG). Annually, 805,000 first or recurrent MIs and 795,000 first or recurrent strokes occur in the USA \[[@CR3]\]. In 2014, 480,000 patients required a PCI and 371,000 patients required a CABG procedure \[[@CR3]\].

Lipids, especially LDL-C, are implicated in the pathogenesis of atherosclerosis and contribute to the development of atherosclerotic lesions \[[@CR1]\]. Current treatment guidelines recommend the use of statins as first-line lipid-lowering therapy (LLT) in patients with clinical ASCVD (i.e., diagnoses of acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin) \[[@CR4]\]. For patients who do not achieve lipid goals on a tolerable dose of statin monotherapy, combination therapy with a statin and a nonstatin LLT is recommended \[[@CR4]\]. Nonstatin LLTs include ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9is) antibodies \[[@CR4]--[@CR6]\]. US guidelines currently recommend the use of PCSK9is for very high-risk patients and LDL-C greater than 70 mg/dL despite treatment with standard background therapy including statins and ezetimibe \[[@CR4]--[@CR6]\].

In clinical trials, PCSK9is demonstrated clinically significant and unprecedented reductions (60--70%) in LDL-C in patients whose LDL-C could not be controlled with a statin and/or ezetimibe \[[@CR7]\]. Notably, reductions in LDL-C were independent of gender across phase 3 clinical trials of PCSK9is \[[@CR8], [@CR9]\]. Additionally, PCSK9is have been shown to reduce the rate of cardiovascular events by 15% to 20% compared with placebo in patients with ASCVD and other risk factors \[[@CR10], [@CR11]\].

Despite the demonstrated clinical benefit of PCSK9is for some patients, access to these medications has been difficult. Barriers to obtaining PCSK9i prescriptions include a requirement for prior authorization, step therapy (i.e., the trial of another medication first), and high prior authorization rejection rates that are not clinically based \[[@CR12]\]. One PCSK9i prior authorization requirement implemented in some health plans requires the prescription to be written by a specialist or cardiologist, which may pose a significant barrier for patients with limited access to cardiologists. The primary objective of this study was to describe the distribution of demographic and clinical characteristics of PCSK9i-eligible patients with clinical ASCVD receiving cardiologist care in the outpatient setting in commercial and Medicare Advantage plans. This high-risk population was of particular interest because disparities in care could lead to an increase in major cardiovascular events. We also examined the characteristics of patients who received a statin and/or ezetimibe prescription from a cardiologist. The results of this study can be used to inform whether requiring a prescription for a PCSK9i from a cardiologist disproportionally limits access to patients with certain characteristics.

Methods {#Sec2}
=======

Data Sources {#Sec3}
------------

This cross-sectional study was based on administrative claims data from Inovalon's Medical Outcomes Research for Effectiveness and Economics Registry (MORE^2^ Registry^®^). The MORE^2^ Registry is a warehouse of healthcare data representing 132 million members in the USA and includes information about enrollment and demographic characteristics, medical encounters (office visits, outpatient services, emergency department visits, hospitalizations, postacute care services), laboratory results, and retail and mail order pharmacy records. The registry includes commercial, Affordable Care Act Marketplace, Medicare Advantage, and managed Medicaid health plans. The MORE^2^ Registry was linked to an external database that provides individual-level data on race/ethnicity, education level, marital status, and household income.

Patients {#Sec4}
--------

The study population included patients at least 18 years of age who were continuously enrolled in commercial or Medicare Advantage health plans during the study period (January 1, 2014, through December 31, 2014) and had evidence of ASCVD recorded on medical claims based on diagnosis or procedure codes (Table [1](#Tab1){ref-type="table"}). Eligible patients had to have filled at least one prescription for statin, ezetimibe, or statin plus ezetimibe combination therapy and have an LDL-C level of at least 70 mg/dL. Statins included atorvastatin, atorvastatin/amlodipine, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, pravastatin/aspirin, rosuvastatin, simvastatin, and simvastatin/sitagliptin.Table 1Diagnosis and procedure codes for identification of ASCVD conditionsASCVD conditionCode(s)Acute coronary syndromesAcute myocardial infarction: ICD-9-CM: 410.xxUnstable angina: ICD-9-CM: 411.xxHistory of myocardial infarctionICD-9-CM: 412.xxMS-DRG: 280--282Stable anginaICD-9-CM: 413.xxCoronary artery revascularizationCPT: 33140, 33141, 33508, 33510--33519, 33521--33523, 33530, 33533--33536, 33572, 35500, 35572, 35600, 92920, 92921, 92924, 92925, 92928, 92929, 92933, 92934, 92937, 92938, 92941, 92943, 92944, 92973, 92975, 92977, 92980--92984, 92995--92996, 00566, 00567HCPCS: C9600--C9608, G0290, G0291, S2205--S2209ICD-9-CM: 36.03, 36.04, 36.06, 36.07, 36.09, 36.11--36.17, 36.19, 36.2, 36.31--36.34, 36.39, 00.45--00.48, 00.66, 17.55, 36.10MS-DRG: 231--236, 246--251Peripheral artery revascularizationCPT: 34051, 34101, 34111, 34201, 34203, 35302--35306, 35311, 35321, 35331, 35341, 35351, 35344, 35361, 35363, 35371, 35372, 35450, 35452, 35454, 35456, 35458, 35459, 35470--35475, 35480--35485, 35490--35495, 35511--35512, 35516, 35518, 35521--35523, 35525, 35526, 35531, 35533, 35535--35540, 35548, 35549, 35551, 35556, 35558, 35560, 35563, 35565, 35566, 35570--35571, 35583, 35585, 35587, 35612, 35616, 35621, 35623, 35626, 35631--35634, 35636--35638, 35646, 35647, 35650, 35651, 35654, 35656, 35661, 35663, 35665, 35666, 35671, 35875, 35876, 35879, 35881, 35883, 35884, 37184--37186, 37201, 37202, 37205--37208, 75960, 75962--75964, 75966, 75968, 93668ICD-9-CM: 38.13--38.16, 38.18, 39.71, 39.73, 00.55, 00.60, 38.10, 39.50, 39.90Peripheral artery diseaseICD-9-CM: 250.70--250.73, 362.30, 362.31--362.33, 433.00, 433.10, 433.20, 433.30, 433.80, 433.90, 434.00, 434.10, 434.90, 440.0x, 440.1x, 440.20--440.24, 440.29, 440.30--440.32, 440.4x, 440.8x, 440.9x, 443.9x, 444.01, 444.09, 444.1x, 444.21, 444.22, 444.81, 444.89, 444.9x, 445.01, 445.02, 445.081, 445.89Ischemic strokeMS-DRG: 061--063HCPCS: G8600--G8602ICD-9-CM: 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91Transient ischemic attackMC-DRG: 069ICD-9-CM: 362.34, 435.xx, 435.1x, 435.2x, 435.3x, 435.8x, 435.9xStroke/transient ischemic attackHCPCS: G8837ICD-9-CM: V12.54*ASCVD* atherosclerotic cardiovascular disease, *CPT* current procedural terminology, *HCPCS* Healthcare Common Procedure Coding System, *ICD-9-CM* International Classification of Diseases, Ninth Revision, Clinical Modification, *MS-DRG* Medicare Severity-Diagnosis Related Group

Study Outcomes {#Sec5}
--------------

Outcomes included (1) whether the patient had at least one outpatient cardiologist visit during the study period, and (2) whether the patient filled at least one prescription for statin, ezetimibe, or statin plus ezetimibe combination therapy written by a cardiologist during the study period.

Statistical Considerations {#Sec6}
--------------------------

The distribution of patient characteristics based on study outcomes was evaluated. Logistic regression models were used to identify patient characteristics associated with an outpatient visit to a cardiologist and with receipt of a statin and/or ezetimibe prescription from a cardiologist. Logistic regression models controlled for age, gender, race or ethnicity, household income, Charlson Comorbidity Index score, comorbidities (hyperlipidemia, chronic kidney disease, hypertension, and diabetes), and patient baseline healthcare resource utilization. The analysis was separately stratified by payer type (commercial or Medicare Advantage).

Compliance with Ethics Guidelines {#Sec7}
---------------------------------

This analysis of deidentified claims data conformed to the Health Insurance Portability and Accountability Act of 1996. Ethics committee approval was not required, as this was a retrospective analysis and no human participants were involved in the study.

Results {#Sec8}
=======

Patients {#Sec9}
--------

A total of 39,322 patients with commercial insurance and 261,898 patients with Medicare Advantage met eligibility criteria and were included in the study. The mean age was 57.4 years for commercially insured patients and 72.4 years for patients with Medicare Advantage (Table [2](#Tab2){ref-type="table"}). Most patients had hypertension (80.5% and 94.0% of commercially insured patients and patients with Medicare Advantage, respectively) and hyperlipidemia (85.8% and 93.2%). Mean Charlson Comorbidity Index score was higher for patients with Medicare Advantage (score 2.7) compared with commercially insured patients (score 1.7).Table 2Demographic and clinical characteristicsCommercial (*N* = 39,322)Medicare Advantage (*N* = 261,898)Age, mean, years57.472.4Gender, *n* female (%)16,194 (41.2)135,157 (51.6)Race or ethnicity, *n* (%) White32,731 (83.2)187,466 (71.6) African American3050 (7.8)45,141 (17.2) Asian/Pacific Islander546 (1.4)3734 (1.4) Hispanic (ethnicity)1800 (4.6)19,155 (7.3) Other race236 (0.6)4402 (1.7) Missing959 (2.4)2000 (0.8)Household income, US\$*, n* (%) \< 25,0003998 (10.2)75,512 (27.7) 25,000--49,9996201 (15.8)89,093 (34.0) 50,000--74,99910,633 (27.0)55,930 (21.4) 75,000--99,9998670 (22.0)17,516 (6.7) 100,000--149,0005909 (15.0)16,829 (6.4) ≥ 150,0003911 (9.9)10,018 (3.8)Select comorbidities, % Chronic kidney disease11.931.4 Diabetes36.856.6 Hyperlipidemia85.893.2 Hypertension80.594.0 Charlson Comorbidity Index, mean score1.72.7 Hospitalizations during study period, mean number0.30.3 Emergency department visits during study period, mean number0.60.8

Patients with a Cardiologist Visit {#Sec10}
----------------------------------

The percentages of commercially insured and Medicare Advantage patients with a visit to a cardiologist during the study period were 56.9% and 61.7%, respectively (Table [3](#Tab3){ref-type="table"}). Patient characteristics associated with a decreased likelihood of a cardiologist visit for both commercially insured patients and those with Medicare Advantage included female gender, chronic kidney disease, and diabetes. Patient characteristics associated with an increased likelihood of a cardiologist visit for both cohorts included household income of at least US\$100,000, hyperlipidemia, hypertension, recent hospitalization, and recent emergency room visit (Fig. [1](#Fig1){ref-type="fig"}).Table 3Outpatient physician visitsCommercial (*N* = 39,322)Medicare Advantage (*N* = 261,898)Cardiologists Patients with a visit, %56.961.7 Number of visits, mean (SD)4.2 (4.9)5.1 (5.8)Primary care physicians Patients with a visit, %82.987.5 Number of visits, mean (SD)7.7 (9.6)12.7 (12.5)Other physicians Patients with a visit, %84.688.9 Number of visits, mean (SD)9.8 (12.8)14.1 (14.3)*SD* standard deviationFig. 1Likelihood of an outpatient cardiologist visit.*CCI* Charlson Comorbidity Index,*CL* confidence limit,*OR* odds ratio

Patients with a Statin and/or Ezetimibe Prescription from a Cardiologist {#Sec11}
------------------------------------------------------------------------

The percentages of commercially insured and Medicare Advantage patients with a prescription for statin and/or ezetimibe were 58.2% and 67.6%, respectively; however, only 27.3% and 22.5% of patients received a statin and/or ezetimibe prescription from a cardiologist (Table [4](#Tab4){ref-type="table"}). Patient characteristics associated with a decreased likelihood of a prescription from a cardiologist for both commercially insured patients and those with Medicare Advantage included female gender, chronic kidney disease, and diabetes. Patient characteristics associated with an increased likelihood of a prescription from a cardiologist for both commercially insured patients and those with Medicare Advantage included hypertension, recent hospitalization, and recent emergency room visit (Fig. [2](#Fig2){ref-type="fig"}).Table 4Statin and/or ezetimibe prescriptionsCommercial (*N* = 39,322)Medicare Advantage (*N* = 261,898)Patients with ≥ 1 statin and/or ezetimibe prescription,  %58.267.6Prescriber: cardiologist Patients with ≥ 1 prescription,  %27.322.5 Number of prescriptions, mean (SD)0.6 (1.5)0.3 (0.8)Prescriber: primary care physician Patients with ≥ 1 prescription,  %51.557.1 Number of prescriptions, mean (SD)1.2 (2.1)1.2 (1.8)Prescriber: other physician Patients with ≥ 1 prescription, %39.847.0 Number of prescriptions, mean (SD)0.8 (1.4)1.0 (1.7)Prescriber: unknown physician type Patients with ≥ 1 prescription, %38.532.9 Number of prescriptions, mean (SD)0.9 (1.6)0.8 (1.6)*SD* standard deviationFig. 2Likelihood of receiving a prescription for statin and/or ezetimibe from a cardiologist.*CCI* Charlson Comorbidity Index,*CL* confidence limit,*OR* odds ratio

Discussion {#Sec12}
==========

In this analysis of patients with ASCVD and risk factors such as LDL-C levels of at least 70 mg/dL, women were significantly less likely than men to have an outpatient visit to a cardiologist. Women were also significantly less likely than men to receive a prescription for a statin and/or ezetimibe from a cardiologist. These observations were made in both commercially insured patients and in patients in Medicare Advantage plans. Likewise in a study of PCSK9i access and cardiovascular outcomes published in 2019, Myers et al. reported that PCSK9i rejection rates were higher in women versus men and that access disparities were associated with higher rates of cardiovascular events \[[@CR13]\].

Women experience many aspects of CVD differently than men---most notably, different symptom patterns for MI (less chest pain, more shortness of breath, nausea/vomiting, and back or jaw pain) \[[@CR14]\]. Although men and women share similar risk factors for CVD, women are disproportionally affected by some of these common risk factors \[[@CR15]\]. For example, elevated levels of LDL-C are a known risk factor for CVD in both genders, and LDL-C levels in postmenopausal women can exceed levels seen in men. Elevation of triglyceride levels increase cardiovascular risk more in women than in men. Notably, statin therapy is as effective at lowering lipid levels in women as in men \[[@CR16]\]. Women also have gender-specific risk factors for CVD, including pregnancy-related risks (hypertension, preeclampsia, and gestational diabetes), oral contraceptive use, and menopause \[[@CR17]\]. Finally, and perhaps most importantly, the number of men and women with CVD, as measured by the 2013--2016 US prevalence of CVD excluding hypertension, is nearly the same (9.6% vs 8.4%, respectively). Likewise, 2016 cardiovascular mortality estimates show that a similar number of men and women die each year from CVD \[[@CR3]\]. The similarity in CVD and mortality rates between men and women underscores the need for parity in access to and utilization of evidence-based, risk-reducing treatment.

Despite the burden of CVD in women, women with CVD experience increased hurdles in accessing healthcare compared with men. For example, a gender bias in referral of women for secondary prevention measures, including cardiac rehabilitation and medications to control hypercholesterolemia, has been observed \[[@CR18], [@CR19]\]. Other studies have shown that women with CVD are less likely to undergo and more likely to experience a delay in coronary angiography during hospitalization \[[@CR20], [@CR21]\]. An analysis of data from the National Health and Nutrition Examination Survey showed that effective cardiac medications (beta-blockers, angiotensin II converting enzyme inhibitors/angiotensin II receptor blockers) used to reduce the risk of death and recurrent coronary events in patients with coronary artery disease are underused in women \[[@CR22]\]. Low income or socioeconomic status, more prevalent in women, is a significant predictor of cardiovascular death or MI \[[@CR23]\]. The 2015 National Healthcare Quality and Disparities Report (based on priority areas defined by the National Quality Strategy established by the Affordable Care Act) noted a disparity in access to healthcare for women in general that requires immediate attention \[[@CR24]\].

Reduction of LDL-C levels to reduce the risk of cardiovascular events is the goal of treatment in patients with ASCVD \[[@CR4]\]. Statins have been shown to effectively reduce levels of LDL-C. Despite the demonstrated efficacy of these medications, studies have shown that women are less likely to receive statin therapies than men \[[@CR22], [@CR25]\]. PCSK9is can be used in patients who need further LDL-C reduction in order to decrease their risk for MI, stroke, and coronary revascularizations \[[@CR4]\]. A study by the American Society for Preventive Cardiology (ASPC) reported significant barriers to patients attempting to fill prescriptions for PCSK9is, including requirements for prior authorization, step therapy, and appeals \[[@CR12]\]. The present analysis extends this finding, suggesting that utilization management criteria that require patients try ezetimibe before a PCSK9i (i.e., step therapy) and require prescriptions for PCSK9i be written by a cardiologist could further obstruct women from accessing these therapies at the same rate as men, reinforcing the gender gap in cardiovascular care.

This study was subject to limitations associated with claims-based analyses, including errors due to miscoding. In addition, we were not able to identity the reason why a cardiologist may have decided not to prescribe LLT for a given patient. For example, some patients may have been receiving a stable and well-tolerated LLT regimen prescribed by another physician, or a patient may have been intolerant to statins or had a contraindication; therefore, we did not analyze prescription patterns between patients who did versus did not see a cardiologist. Given the observational and cross-sectional design of the study, confounding factors other than those accounted for in the multivariate analysis could have affected the results. Moreover, the percentage of patients under the care of a cardiologist may be underestimated if patients did not have a visit during the data collection period but had seen a cardiologist previously. Results may not be representative of patients who are uninsured or underinsured or who have different demographic or clinical characteristics.

Conclusion {#Sec13}
==========

In summary, results demonstrated that women with ASCVD were less likely than men to visit a cardiologist and to receive a prescription for a statin and/or ezetimibe from a cardiologist. Utilization management criteria that require prescriptions be written by a cardiologist may disproportionally limit women with ASCVD access to needed LLTs.
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